St. Jude launches neurostim device that can handle software updates; FDA to set conflict-of-interest rules for advisory panel members;

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> St. Jude Medical ($STJ) won FDA approval for a neurostimulation system to treat chronic pain that allows spinal cord stimulation technology upgrades, as they are approved, to be made via software updates. Release

> Roche's ($RHHBY) Ventana medical systems will work with a Danish drug company, in part, to develop an immunohistochemistry companion diagnostic test that detects tissue factor in patient tumor samples. Release

> Escalon Medical ($ESMC) in Pennsylvania gained the FDA's 510(k) clearance for a new tablet-based ultrasound imaging system. Release

> Evonik will open research sites in the U.S and Germany focused on developing biomaterials and polymers for implantable medical technology. Story

> The FDA has decided that experts who serve on agency advisory panels that evaluate new medical devices and drugs must disclose conflicts of interest. Story

Biotech News

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie gets out of the way as the EU prepares for trial transparency. More

> Merck and Ferring team up on anti-bleeding drug for the developing world. News

> GTx's CEO finds the door as the company moves on from a PhIII failure. Article

Pharma News

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned first-hand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> Meda spurns Mylan takeover bid. News

> FDA's OK of opioid overdose treatment doesn't quell backlash over Zohydro. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.